CClinicalTrials.gg
Not yet recruitingNCT06617039Updated Sep 27, 2024

The Impact of Low-Dose Esketamine Combined With Ciprofol on the Quality of Early Postoperative Recovery Among Elderly Patients Undergoing Painless Gastroscopy

An interventional study of Remifentanil and ciprofol and esketamine 0.3mg/kg and ciprofol in Quality of Postoperative Recovery, sponsored by Subei People's Hospital of Jiangsu Province. Not yet recruiting at 1 site in China. Open to participants aged 60 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by Subei People's Hospital of Jiangsu Province · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
376
Allocation
Randomized
Ages
60 Years to 75 Years
Sex
All
01

Study summary

To explore the impact of esketamine combined with ciprofol on the quality of early postoperative recovery in elderly patients undergoing painless gastroscopy, as well as the effectiveness and safety of this regimen.

02

Conditions studied

  • Quality of Postoperative Recovery
03

In context

Lead sponsor

Subei People's Hospital of Jiangsu Province is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

    1. Scheduled painless gastroscopy examination and treatment

      1. Age 60-75 years old
      1. ASA grade Ⅰ-Ⅱ
      1. The respiratory tract is unobstructed and there is no difficult airway
      1. No history of allergy to etomidate and cyclopropofol
      1. Participants with normal heart, liver, lung, and kidney functions
      1. Able to complete the QoR-15, MMSE, and HADS scale assessments
      1. lnformed consent, voluntary participation in the trial, and signed by the patient informed consent

Exclusion criteria

Exclusion Criteria:

    1. Participants with concurrent dysfunction of major organs.

      1. Participants with a history of mental illness and abuse of sedative drugs
      1. Participants with allergies or contraindications to the study drugs
      1. Participants with severe visual, auditory, or speech communication impairments
      1. Participants with acute gastrointestinal inflammation or obstruction
      1. History of uncontrolled diabetes, hypertension, and hypotension
      1. Participants with malignant tumors, severe hyperkalemia, bronchial asthma, or excessive obesity (BMI > 30kg/m2)
      1. Participants with aneurysmal vascular diseases of the thoracic and abdominal aorta, intracranial and peripheral arterial vessels.
      1. Unable to cooperate with the QoR-15, MMSE, and HADS scale assessments
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
376 participants (estimated)

Study arms

  • Active comparator
    Ciprofol group (C group)

    Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.

    Drug: Ciprofol

  • Experimental
    The group of remifentanil 0.5ug/kg combined with ciprofol(R group)

    R group will be started with remifentanil 0.5ug/kg and ciprofol 0.2-0.4 mg/kg.

    Drug: Remifentanil and ciprofol

  • Experimental
    The group of esketamine 0.3mg/kg combined with ciprofol(E1 group)

    E1 group will be started with esketamine 0.3mg/kg and ciprofol 0.2-0.4 mg/kg.

    Drug: esketamine 0.3mg/kg and ciprofol

  • Experimental
    The group of esketamine 0.5mg/kg combined with ciprofol(E2 group)

    E2 group will be started with esketamine 0.5mg/kg and ciprofol 0.2-0.4 mg/kg.

    Drug: esketamine 0.5mg/kg and ciprofol

Interventions

  • DrugRemifentanil and ciprofol

    R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.

  • Drugesketamine 0.3mg/kg and ciprofol

    Anesthesia induction was initiated by esketamine 0.3mg/kg, followed by ciprofol 0.2-0.4mg/kg.

  • Drugesketamine 0.5mg/kg and ciprofol

    Anesthesia induction was initiated by esketamine 0.5mg/kg, followed by ciprofol 0.2-0.4mg/kg.

  • DrugCiprofol

    Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.

06

What researchers measure

Primary outcomes

  1. postoperative day 1(POD1) Quality of Recovery(QoR)-15 questionnaire score

    Quality of life will be evaluated using Quality of Recovery(QoR)-15 questionnaire score at postoperative day 1(minimum value : 0, maximum value : 150, the higher the score, the better the result)

    Time frame: Baseline (30 min before surgery), postoperative day 1

Secondary outcomes

  1. postoperative day 3(POD3) Quality of Recovery(QoR)-15 questionnaire score

    Quality of life will be evaluated using Quality of Recovery(QoR)-15 questionnaire score at postoperative day 3(minimum value : 0, maximum value : 150, the higher the score, the better the result)

    Time frame: Postoperative day 3 and 7

  2. Cognitive function assessment

    A Mini-Mental State Examination (MMSE) is a set of 11 questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory). MMSE has a maximum total score of 30, with higher scores manifesting a better cognitive performance.

    Time frame: Baseline (30 min before surgery), postoperative day 1,3 and 7

  3. Hospital anxiety and depression scale ( HADS ) score.

    Postoperative anxiety and depression scores will be measured by the Hospital Anxiety and Depression Scale, on the morning(8-10 am) of postoperative days (PODs) 1,3 and 7 , a score of 8 points or higher will be diagnosed as depression or anxiety.

    Time frame: Baseline (30 min before surgery), postoperative day 1,3 and 7

  4. Dosage of ciprofol

    Consumption of ciprofol during endoscopic examination

    Time frame: During endoscopic examination

  5. Heart rate (HR)

    Throughout the procedure, the heart rate (HR) was continuously monitored.

    Time frame: Baseline,during surgery and arrived at PACU (up to 30 minutes after surgery)

  6. Pulse oxygen saturation (SpO2)

    Throughout the procedure, the pulse oxygen saturation (SpO2) were continuously monitored.

    Time frame: Baseline, during surgery and arrived at PACU (up to 30 minutes after surgery)

  7. Mean blood pressure (MBP)

    Throughout the procedure, the mean blood pressure (MBP) was measured at 1-minute intervals.

    Time frame: Baseline, during surgery and arrived at PACU (up to 30 minutes after surgery)

  8. Patient satisfaction levels

    The patients express their satisfaction with procedures on a visual analogue score, ranging from 0 to 10, where 0 is the minimum and 10 is the maximum satisfaction level.

    Time frame: 30 minutes at recovery room.

Other outcomes

  1. The incidence of all drug-related adverse events

    All drug-related adverse events including bradycardia, hypotension, tachycardia, hypertension, arrhythmia, nystagmus, hypersalivation, euphoria, emergence agitation, hallucinations, dreaminess and nightmares during surgery or before discharge.etc.Patients will be followed up for 3 days consecutively(at 8-10am).

    Time frame: Within 72hours after surgery

07

Study locations

1 site
  • Subei People's Hospital of Jiangsu Province
    Yangzhou, Jiangsu 225001, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06617039
Lead sponsor
Subei People's Hospital of Jiangsu Province
Responsible party
Ju GAO (Study Director, Subei People's Hospital of Jiangsu Province) — Principal investigator
First posted
Sep 27, 2024
Start date
Oct 2024 (estimated)
Primary completion
May 2025 (estimated)
Completion
May 2025 (estimated)
Last update
Sep 27, 2024

Study contacts

Ju Gao
Contact
doctor2227@163.com
18051063988
Xing Lin
Contact
17696528825@163.com
17696528825

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion